TwistPak®: Mixing platform for swine vaccines brings convenience and flexibility

Ingelheim, Germany,

  • TwistPak® allows for fresh mixing of Ingelvac CircoFLEX® and Ingelvac MycoFLEX® on farm in less than 5 seconds
  • In 2021, TwistPak® received Red Dot Design Award, highlighting its ease of use and hygienic application 
  • Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being

Boehringer Ingelheim, a global leader in animal health, announces its latest innovation: TwistPak®, a revolutionary mixing platform. It enables swine producers to combine two vaccines, Ingelvac CircoFLEX® and Ingelvac MycoFLEX®, in a convenient, fast and flexible way. TwistPak® will be globally available in all registered presentation sizes starting April this year.

Red Dot Design Award for innovative vaccine bottle design

Reddot winner 2021 logo

The patented TwistPak® technology incorporates a unique, hygienic interlock at the bottom of each bottle to connect two bottles with a simple twist. This action creates one single mixing chamber, which fits in all standard vaccination devices. The new TwistPak® vaccine bottles, enhanced with an ergonomic design, are a result of advanced manufacturing technologies. This is why TwistPak®, jointly co-created with the industrial design and product development company DESIGNquadrat, was awarded the Red Dot Design Award 2021, category product design.

Enhanced speed and convenience for freshly mixed vaccines

Packshot Ingelavac Mycoflex and Ingelvac Circoflex

Customers today expect mixing systems to provide confidence. They want to be sure that the substances are properly mixed, the mixing process is easy, hygienic, safe as well as fast.1 Currently, freshly mixing two vaccines requires a transfer needle. The innovative TwistPak® bottle simplifies the mixing process while retaining the flexibility of using the products as a monovalent or combined vaccine.

 

Empowering customers to create and customize pig herd vaccination protocols

Eva Joras, Global Brand Manager at Boehringer Ingelheim shares: “TwistPak® revolutionizes how vaccines are mixed. The mixing platform combines the best of both worlds: the unparalleled quality and efficacy of freshly mixed vaccines with the convenience of ready-to-use solutions. The new mixing platform enhances a market-leading product range: Through the flexibility of our FLEX® franchise, we are empowering our customers to create the best and most appropriate vaccination protocol for the health of their herds whilst significantly improving the vaccination process.”

PCV2 virus and Porcine Circovirus‐Associated Disease (PCVAD)

Man and Woman vaccinating piglets

Ingelvac CircoFLEX® immunize against the PCV2 virus, which causes Porcine Circovirus‐Associated Disease (PCVAD). Ingelvac MycoFLEX® prevents pigs from falling ill with the Porcine Respiratory Disease Complex (PRDC), caused by Mycoplasma hyopneumoniae (Mhyo). Both pathogens are highly prevalent in pig farming worldwide.

Boehringer Ingelheim was the first company to introduce mixable PCV2 and Mhyo swine vaccines to the market in 2009. The company’s aim was to reduce the number of injections, as they can be a source of stress for piglets. Fewer injections resulting from the mixing of vaccines increase the well-being of pigs and decrease the workload for swine producers, without compromising efficacy and safety.

The new TwistPak® presentations will be first available in South Korea, followed by China and Southeast Asia. Subsequently, Boehringer Ingelheim will roll them out in more than 60 countries in order to enhance the experience of our customers globally.

References

1Bahlmann, J. (2020) Swine producer needs for fresh on-site mixing of PCV-2 / M.hyo vaccines in USA, Germany and China. Proceedings IPVS 2020, Rio de Janeiro.  p.680 

 

About the Red Dot Design Award

In order to appraise the diversity in the field of design in a professional manner, the Red Dot Design Award breaks down into the three disciplines of Red Dot Award: Product Design, Red Dot Award: Brands & Communication Design and Red Dot Award: Design Concept. With more than 18,000 entries, the Red Dot Award is one of the world’s largest design competitions. In 1955, a jury convened for the first time to assess the best designs of the day. In the 1990s, Red Dot CEO Professor Dr. Peter Zec developed the name and brand of the award. Ever since, the sought-after distinction “Red Dot” has been the revered international seal of outstanding design quality. The award winners are presented in the yearbooks, museums and online. More information is available at www.red-dot.de.

About DESIGNquadrat

DESIGNquadrat and DDS are specialized teams for industrial design and product development. For more than 15 years, the teams have been developing products using a holistic approach.

Boehringer Ingelheim Animal Health

Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, farmers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
For more information visit: https://www.boehringer-ingelheim.com/animal-health

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com 

Intended audiences

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contacts

Services

Print this Press Release

Tags

Press Release Subscription

Signup here to the Boehringer Ingelheim Newsletter to receive press-releases via email.